Oncology Clinical Trial Monitor is a continuously updated dashboard, highlighting the global immuno-oncology clinical development landscape and clinical outcomes for key standards of care. This…
Oncology Clinical Trial Monitor is a continuously updated dashboard, highlighting the global immuno-oncology clinical development landscape and clinical outcomes for key standards of care. This…
OA pain is the second largest segment of the overall chronic pain market, affecting more than 90 million patients in the G7. The OA pain market represents a lucrative opportunity for drug…
Despite the large number of currently marketed antiepileptic drugs (AEDs), important unmet needs remain for new therapies to treat refractory epilepsy and seizure syndromes such as Lennox-Gastaut…
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells (RBCs) that distorts them into a sickle shape. This sickling leads to…
According to Clarivate epidemiology, cognitive dysfunction (e.g., impaired attention / vigilance, memory, executive function) occurs in the vast majority of diagnosed schizophrenia patients and has…
Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, represents the largest segment of the chronic pain therapy market. Prescription treatment…
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction of melanocytes. The etiology is multifactorial; both genetic and environmental factors are implicated in disease…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country,…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries. We report the diagnosed prevalence of vitiligo for each country, as well as…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country…
Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance,…